H1512

Haloperidol

≥98% (TLC), powder, dopamine receptor antagonist

• Sinónimos: 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone
• Fórmula empírica (notación de Hill): C₂₁H₂₃ClFNO₂
• Número de CAS: 52-86-8
• Peso molecular: 375.86
• EC Number: 200-155-6
• MDL number: MFCD00051423
• UNSPSC Code: 12352200
• PubChem Substance ID: 24277917
• NACRES: NA.77

Propiedades

• Nombre del producto: Haloperidol, powder
• form: powder
• Quality Level: 200
• color: white
• solubility: 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.39 mg/mL; 0.1 M HCl: 3 mg/mL; DMSO: soluble; H₂O: insoluble; ethanol: soluble
• originator: Johnson & Johnson
• SMILES string: OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3
• InChI: 1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
• InChI key: LNEPOXFFQSENCJ-UHFFFAOYSA-N
• Gene Information: human ... ABCB1(5243) , ADRA1A(148) , ADRA2A(150) , ADRA2C(152) , CHRM1(1128) , DRD2(1813) , DRD3(1814) , DRD4(1815) , EBP(10682) , HRH1(3269) , HTR2A(3356) , HTR2C(3358) , HTR7(3363) , KCNH1(3756) , KCNH2(3757) , PRNP(5621) ; rat ... Adra1a(29412) , Adra2a(25083) , Chrm1(25229) , Chrm2(81645) , Drd1a(24316) , Drd2(24318) , Drd3(29238) , Drd4(25432) , Hrh1(24448) , Htr1a(24473) , Htr1b(25075) , Htr2a(29595) , Htr2c(25187) , Oprs1(29336) , Slc6a3(24898) , Slc6a4(25553)

Descripción

Application

Haloperidol has been used:

• in ethanol to serves as an inhibitor of Erg2p
• to address the mechanism of haloperidol in ferroptosis using hepatocellular carcinoma cells: Hep G2 and Huh-7 cell lines
• in receptor internalization assay
• as an antipsychotic drug in Dulbecco′s Modified Eagle medium

Biochem/physiol Actions

Haloperidol is a butyrophenone antipsychotic. It is also classified as a neuroleptic (powerful tranquilizer). Haloperidol acts as a D2, D3, and D4 dopamine receptor antagonist and thus causes Parkinson′s disorder. It also has a negative effect on the central nervous system.

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS06,GHS08
• signalword: Danger
• hcodes: H301,H315,H317,H319,H335,H361
• pcodes: P202 - P261 - P280 - P301 + P310 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
• target_organs: Respiratory system
• Storage Class: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk_germany: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable